These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
618 related articles for article (PubMed ID: 28854296)
1. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. Locher C; Koechlin H; Zion SR; Werner C; Pine DS; Kirsch I; Kessler RC; Kossowsky J JAMA Psychiatry; 2017 Oct; 74(10):1011-1020. PubMed ID: 28854296 [TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122 [TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028 [TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277 [TBL] [Abstract][Full Text] [Related]
5. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis. Gosmann NP; Costa MA; Jaeger MB; Frozi J; Spanemberg L; Manfro GG; Cortese S; Cuijpers P; Pine DS; Salum GA Psychol Med; 2023 Jul; 53(9):3783-3792. PubMed ID: 37278215 [TBL] [Abstract][Full Text] [Related]
6. Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis. Mills JA; Strawn JR J Am Acad Child Adolesc Psychiatry; 2020 Nov; 59(11):1240-1251. PubMed ID: 31682918 [TBL] [Abstract][Full Text] [Related]
7. Vortioxetine for depression in adults. Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828 [TBL] [Abstract][Full Text] [Related]
8. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920 [TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Jakubovski E; Johnson JA; Nasir M; Müller-Vahl K; Bloch MH Depress Anxiety; 2019 Mar; 36(3):198-212. PubMed ID: 30479005 [TBL] [Abstract][Full Text] [Related]
10. How to address the placebo response in the prescription SSRIs and SNRIs in children and adolescents. Koechlin H; Kossowsky J; Gaab J; Locher C Expert Opin Drug Saf; 2018 Jun; 17(6):537-540. PubMed ID: 29781324 [TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
12. Trajectory and magnitude of response in adults with anxiety disorders: a Bayesian hierarchical modeling meta-analysis of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and benzodiazepines. Mendez EM; Mills JA; Suresh V; Stimpfl JN; Strawn JR CNS Spectr; 2024 Jun; 29(3):187-196. PubMed ID: 38523533 [TBL] [Abstract][Full Text] [Related]
13. The Impact of Antidepressant Dose and Class on Treatment Response in Pediatric Anxiety Disorders: A Meta-Analysis. Strawn JR; Mills JA; Sauley BA; Welge JA J Am Acad Child Adolesc Psychiatry; 2018 Apr; 57(4):235-244.e2. PubMed ID: 29588049 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for social anxiety disorder (SAnD). Williams T; Hattingh CJ; Kariuki CM; Tromp SA; van Balkom AJ; Ipser JC; Stein DJ Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001206. PubMed ID: 29048739 [TBL] [Abstract][Full Text] [Related]
15. Antidepressants for people with epilepsy and depression. Maguire MJ; Marson AG; Nevitt SJ Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531 [TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis. Wang Z; Whiteside SPH; Sim L; Farah W; Morrow AS; Alsawas M; Barrionuevo P; Tello M; Asi N; Beuschel B; Daraz L; Almasri J; Zaiem F; Larrea-Mantilla L; Ponce OJ; LeBlanc A; Prokop LJ; Murad MH JAMA Pediatr; 2017 Nov; 171(11):1049-1056. PubMed ID: 28859190 [TBL] [Abstract][Full Text] [Related]